Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1298310 | 0.83 | ALOX15 (0.48) | CYP3A4TDP1ALOX15ALDH1A1CYP1A2 | |
| SCHEMBL28729858 | 0.78 | ALOX15 (0.43) | CYP3A4TDP1ALOX15ALDH1A1CYP1A2 | |
| SCHEMBL29518416 | 0.78 | ALOX15 (0.43) | CYP3A4TDP1ALOX15ALDH1A1CYP1A2 | |
| SCHEMBL11028071 | 0.77 | ATAD2 (0.45) | ATAD2CYP3A4TSHRMAPK1TDP1 | |
| SCHEMBL8770711 | 0.74 | ALDH1A1 (0.55) | CYP3A4TSHRMAPK1TDP1ALDH1A1 | |
| SCHEMBL11350152 | 0.73 | GRIN2D (0.42) | TDP1ALOX15ALDH1A1CYP1A2KDM4E | |
| SCHEMBL13104456 | 0.73 | GPR3 (0.40) | TDP1ALOX15ALDH1A1CYP1A2KDM4E | |
| SCHEMBL11510152 | 0.72 | ALOX15 (0.34) | TDP1ALOX15ALDH1A1 | |
| SCHEMBL12926912 | 0.71 | ALOX15 (0.37) | CYP3A4TSHRMAPK1TDP1ALOX15 | |
| SCHEMBL14629464 | 0.71 | SMN1; SMN2 (0.52) | CYP3A4TSHRMAPK1TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897868-B2 | Heterocyclic inhibitors of PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2024-02-13 | — | — | US | disclosed |
| US-20220002271-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2022-01-06 | — | — | US | disclosed |
| US-11091466-B2 | Heterocyclic inhibitors of PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2021-08-17 | — | — | US | disclosed |
| US-20200207743-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091466-B2 | Heterocyclic inhibitors of PCSK9 | PCSK9, PCSK7, PCSK6 | ATAD2 3225/4885CYP3A4 969/4885TSHR 2834/4885 |
| US-20220002271-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | PCSK9, PCSK6, PCSK7 | ATAD2 3251/4885CYP3A4 920/4885TSHR 2711/4885 |
| US-11897868-B2 | Heterocyclic inhibitors of PCSK9 | PCSK9, PCSK6, PCSK7 | ATAD2 3251/4885CYP3A4 920/4885TSHR 2711/4885 |
| US-20200207743-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | PCSK9, PCSK7, PCSK6 | ATAD2 3225/4885CYP3A4 969/4885TSHR 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.